AI Article Synopsis

  • The study investigates the link between GABAA/benzodiazepine receptor binding and cognitive function in schizophrenia using advanced imaging techniques.
  • Results indicate that lower receptor binding correlates with worse performance on cognitive tasks in individuals with schizophrenia compared to non-psychiatric controls.
  • The findings point to a potential role of GABA in cognitive deficits associated with schizophrenia, suggesting directions for future research to further explore this relationship.

Article Abstract

Background: The role of the inhibitory neurotransmitter gamma aminobutyric acid (GABA) in schizophrenia has previously been investigated using postmortem material. Recently, using single photon emission tomography (SPET) with the selective benzodiazepine antagonist 123I-Iomazenil as the radioligand, we have demonstrated an in vivo relationship between reduced GABAA/benzodiazepine receptor binding and the severity of positive symptomatology in schizophrenia. The present study aimed to build on this using the same in vivo scanning techniques, and relating findings to cognitive functioning.

Methods: Ten nonpsychiatric control subjects and 15 schizophrenic patients, matched for age and handedness, were scanned. A battery of neuropsychologic tests was also administered.

Results: Correlational analysis revealed a pattern of increased correlations between GABAA/benzodiazepine receptor binding and task performance, in the schizophrenic group compared to the control group.

Conclusions: Findings are preliminary but suggest a relationship between reduced GABAA/benzodiazepine receptor binding and poorer cognitive functioning, involving memory and visual attention processes, in the schizophrenic group but not in the control group. A role for GABA in the pathophysiology of schizophrenia is suggested. Limitations of the present study and suggestions for future research are discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-3223(97)00300-4DOI Listing

Publication Analysis

Top Keywords

gabaa/benzodiazepine receptor
16
receptor binding
16
cognitive functioning
8
relationship reduced
8
reduced gabaa/benzodiazepine
8
schizophrenic group
8
gabaa/benzodiazepine
4
functioning gabaa/benzodiazepine
4
receptor
4
binding
4

Similar Publications

Agonists of Benzodiazepine (BZD) receptor are exhaustively used in the control of muscle spasms, seizure, anxiety, and insomnia. BZDs have some unwanted effects; therefore, the development of new BZD receptor agonists with better efficacy and fewer unwanted effects is one of the subjects of interest. In this study, based on the pharmacophore/receptor model of the BZD binding site of GABA receptors, a series of new 2-substituted-5-(4-chloro-2-phenoxy)phenyl-1,3,4-oxadiazole derivatives (-) were designed.

View Article and Find Full Text PDF

Traumatic brain injury (TBI) modelled by lateral fluid percussion-induction (LFPI) in rats is a widely used experimental rodent model to explore and understand the underlying cellular and molecular alterations in the brain caused by TBI in humans. Current improvements in imaging with positron emission tomography (PET) have made it possible to map certain features of TBI-induced cellular and molecular changes equally in humans and animals. The PET imaging technique is an apt supplement to nanotheranostic-based treatment alternatives that are emerging to tackle TBI.

View Article and Find Full Text PDF
Article Synopsis
  • - A new series of chemical compounds, 5-(2-aryloxy-4-nitrophenyl)-4H-1,2,4-triazoles and 5-(2-aryloxy-3-pyridyl)-4H-1,2,4-triazoles, were created and tested for their ability to interact with benzodiazepine receptors and prevent seizures.
  • - These new compounds showed similar to even better binding affinity to the GABA/benzodiazepine receptor complex compared to diazepam, a common anti-seizure medication.
  • - The studies indicated a strong correlation between the compounds' lipophilicity (how well they dissolve in fats) and how quickly
View Article and Find Full Text PDF

Translational Studies in the Complex Role of Neurotransmitter Systems in Anxiety and Anxiety Disorders.

Adv Exp Med Biol

February 2020

Department of Neurobiology, Groningen Institute for Evolutionary Life Sciences (GELIFES), University of Groningen, Groningen, The Netherlands.

Discovery of innovative anxiolytics is severely hampering. Existing anxiolytics are developed decades ago and are still the therapeutics of choice. Moreover, lack of new drug targets forecasts a severe jeopardy in the future treatment of the huge population of CNS-diseased patients.

View Article and Find Full Text PDF

Phlorotannin supplement (PS) is a natural hypnotic substrate that modulates γ-aminobutyric acid type A (GABA)-benzodiazepine (BZD) receptors. However, there is a lack of functional data assessing the role of individual components of PS, such as Dieckol, as allosteric activators of GABA receptors (GABAR). Using the whole cell patch clamp technique, we demonstrated that PS functionally enhanced the activity of GABA-BZD receptors in a heterologous system and in primary cultured neurons.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!